DrugPatentWatch Database Preview
Drugs in Development Information for PF-06463922
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for PF-06463922?
PF-06463922 is an investigational drug.
There have been 12 clinical trials for PF-06463922.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 7th 2017.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Lymphoma, Large-Cell, Anaplastic. The leading clinical trial sponsors are Pfizer, National Cancer Institute (NCI), and University of Milano Bicocca.
There are eleven US patents protecting this investigational drug and one hundred and sixty international patents.
Summary for PF-06463922
| US Patents | 11 |
| International Patents | 160 |
| US Patent Applications | 34 |
| WIPO Patent Applications | 30 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2017-04-07) |
| Vendors | 41 |
Recent Clinical Trials for PF-06463922
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Lorlatinib in ALK Inhibitor‑Treated ALK‑Positive NSCLC in China | Pfizer | Phase 2 |
| Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-Small Cell Lung Cancer (The NCI-NRG ALK Master Protocol) | National Cancer Institute (NCI) | Phase 2 |
| A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma | Pfizer | Phase 2 |
Clinical Trial Summary for PF-06463922
Top disease conditions for PF-06463922
Top clinical trial sponsors for PF-06463922
US Patents for PF-06463922
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-06463922 | Start Trial | Substituted macrocycles useful as kinases inhibitors and methods of use thereof | Teligene Ltd. (Suzhou, CN) | Start Trial |
| PF-06463922 | Start Trial | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | Start Trial |
| PF-06463922 | Start Trial | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | Start Trial |
| PF-06463922 | Start Trial | Treatment of cancer using anti-CD19 Chimeric Antigen Receptor | The Trustees of the University of Pennsylvania (Philadelphia, PA) Novartis AG (Basel, CH) | Start Trial |
| PF-06463922 | Start Trial | Crystalline form of lorlatinib free base | Pfizer Inc. (New York, NY) | Start Trial |
| PF-06463922 | Start Trial | Macrocyclic derivatives for the treatment of diseases | Pfizer Inc. (New York, NY) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-06463922
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-06463922 | China | 107207528 | 2034-08-20 | Start Trial |
| PF-06463922 | European Patent Office | 3183256 | 2034-08-20 | Start Trial |
| PF-06463922 | Japan | 2017525716 | 2034-08-20 | Start Trial |
| PF-06463922 | Argentina | 102035 | 2034-07-21 | Start Trial |
| PF-06463922 | Australia | 2015292744 | 2034-07-21 | Start Trial |
| PF-06463922 | Brazil | 112017001183 | 2034-07-21 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
